Skip to main content
SpringerLink
Log in

Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy

  • Chapter
  • First Online:
Cardiovascular Complications in Cancer Therapy

Part of the book series: Current Clinical Pathology ((CCPATH))

  • 768 Accesses

Abstract

Traditional chemotherapeutics are essential tools in the management of cancer patients. Nevertheless, these drugs are burdened by some degree of cardiovascular toxicity. Anthracycline-induced toxicity has been historically the most studied, but also the use of other drugs can be limited by a certain risk of cardiac and vascular toxicities. Here we acknowledge the main mechanistic insights, and we describe the different aspects of cardiotoxicity of these drugs, highlighting the different cellular compartments and cardiovascular components affected.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brutsaert DL. Cardiac endothelial–myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev. 2003;83:59–115.

    Article  CAS  PubMed  Google Scholar 

  2. Tirziu D, Giordano FJ, Simons M. Cell communications in the heart. Circulation. 2010;122:928–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhao Y, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA. Neuregulins promote survival and growth of cardiac myocytes. J Biol Chem. 1998;273:10261–9.

    Article  CAS  PubMed  Google Scholar 

  4. Park K-A, Park WJ. Endothelial dysfunction: clinical complications in cardiovascular disease and therapeutic approaches. J Korean Med Sci. 2015;30:1213–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Morganti M, Carpi A, Nicolini A, Gorini I, Glaviano B, Fini M, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother. 2002;56:317–24.

    Article  CAS  PubMed  Google Scholar 

  6. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol. 2013;40:186–98.

    Article  CAS  PubMed  Google Scholar 

  7. Di Lisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, et al. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. Int J Cardiol. 2017;227:11–7.

    Article  PubMed  Google Scholar 

  8. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos M-A, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38:473–83.

    Article  CAS  PubMed  Google Scholar 

  9. Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, et al. From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview. Antioxid Redox Signal. 2017; https://doi.org/10.1089/ars.2016.6930. [Epub ahead of print]

  10. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760:267–71.

    Article  CAS  PubMed  Google Scholar 

  11. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms. Redox Biol. 2013;1:244–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wojcik T, Buczek E, Majzner K, Kolodziejczyk A, Miszczyk J, Kwiatek W, et al. Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells. Toxicol In Vitro. 2015;29(3):512–21.

    Article  CAS  PubMed  Google Scholar 

  13. Krohn K. Topics in current chemistry. In: Anthracycline chemistry and biology: biological occurrence and biosynthesis, synthesis and chemistry. New York: Springer; 2008.

    Google Scholar 

  14. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.

    Article  CAS  PubMed  Google Scholar 

  15. Majzner K, Wo’jcik T, Szafraniec E, Łukawska M, Oszczapowicz I, Chłopicki S, et al. Raman microspectroscopic investigation on nuclear accumulation of doxorubicin, daunorubicin and their epimers in endothelium; relationship with cytotoxicity. Analyst. 2015;140:2302–10.

    Article  CAS  PubMed  Google Scholar 

  16. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Friedberg EC. Out of the shadows and into the light: the emergence of DNA repair. Trends Biochem Sci. 1995;20:381.

    Article  CAS  PubMed  Google Scholar 

  18. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science. 2001;294:1713–6.

    Article  CAS  PubMed  Google Scholar 

  19. Feng R, Zhai WL, Yang HY, Jin H, Zhang QX. Induction of ER stress protects gastric cancer cells against apoptosis induced by cisplatin and doxorubicin through activation of p38 MAPK. Biochem Biophys Res Commun. 2011;406:299–304.

    Article  CAS  PubMed  Google Scholar 

  20. Diers AR, Broniowska KA, Hogg N. Nitrosative stress and redox-cycling agents synergize to cause mitochondrial dysfunction and cell death in endothelial cells. Redox Biol. 2013;1:1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Faneyte IF, Kristel PMP, Van De Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res. 2004;24:2931–40.

    CAS  PubMed  Google Scholar 

  22. Bains OS, Szeitz A, Lubieniecka JM, Cragg GE, Grigliatti TA, Riggs KW, et al. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther. 2013;347:375–87.

    Article  CAS  PubMed  Google Scholar 

  23. Tewey K, Rowe T, Yang L, Halligan B, Liu L. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–8.

    Article  CAS  PubMed  Google Scholar 

  24. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430–40.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–42.

    Article  PubMed  Google Scholar 

  26. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992;1132:43–8.

    Article  CAS  PubMed  Google Scholar 

  27. Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, et al. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. J Pharmacol Exp Ther. 2013;344(2):467–78.

    Article  CAS  PubMed  Google Scholar 

  28. Herbrecht R, Cernohous P, Engert A, Le Gouill S, Macdonald D, Machida C, et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol. 2013;24(10):2618–23.

    Article  CAS  PubMed  Google Scholar 

  29. Toldo S, Goehe RW, Lotrionte M, Mezzaroma E, Sumner ET, Biondi-Zoccai GGL, et al. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. PLoS One. 2013;8:4–11.

    Article  Google Scholar 

  30. Kaushal V, Kaushal GP, Mehta P. Differential toxicity of anthracyclines on cultured endothelial cells. Endothelium. 2004;11:253–8.

    Article  CAS  PubMed  Google Scholar 

  31. Grover S, Lou PW, Bradbrook C, Cheong K, Kotasek D, Leong DP, et al. Early and late changes in markers of aortic stiffness with breast cancer therapy. Intern Med J. 2015;45:140–7.

    Article  CAS  PubMed  Google Scholar 

  32. Krystal JI, Reppucci M, Mayr T, Fish JD, Sethna C. Arterial stiffness in childhood cancer survivors. Pediatr Blood Cancer. 2015;62:1832–7.

    Article  PubMed  Google Scholar 

  33. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15(7):1025–32.

    Article  CAS  PubMed  Google Scholar 

  34. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. Epub 2007 Jul 17

    Article  CAS  PubMed  Google Scholar 

  35. Lestuzzi C, Tartuferi L, Corona G. Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations. Breast J. 2011;17:564–5.

    Article  CAS  PubMed  Google Scholar 

  36. Miura K, Kinouchi M, Ishida K, Kinouchi M, Ishida K, Fujibuchi W, et al. 5-FU metabolism in cancer and orally-administrable 5-FU drugs. Cancer (Basel). 2010;2:1717–30.

    Article  CAS  Google Scholar 

  37. Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, et al. Gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis. 2001;4:163–73.

    Article  CAS  PubMed  Google Scholar 

  38. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects on probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 2003;42:304–8.

    Article  CAS  PubMed  Google Scholar 

  39. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500–5.

    Article  CAS  PubMed  Google Scholar 

  40. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48:9–17.

    Article  CAS  PubMed  Google Scholar 

  41. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525–33.

    Article  CAS  PubMed  Google Scholar 

  42. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al. Prophylactic options in patients with 5-fluorouracil associated cardiotoxicity. Br J Cancer. 2003;88:1507–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11:46–9.

    Article  PubMed  Google Scholar 

  44. Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, Miraglia N, Sannolo N, Vanacore D, Stiuso P, Caraglia M. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett. 2014;227(3):151–6.

    Article  CAS  PubMed  Google Scholar 

  45. Mazarakis A, Goudevenos J, Kounis NG, et al. Coronary vasospasm induced by cytostatic drugs: Kounis syndrome seems to be the most likely culprit. Hell J Cardiol. 2013;54:482–5.

    Google Scholar 

  46. Fontanella C, Aita M, Cinausero M, Aprile G, Baldin MG, Dusi V, et al. Capecitabine induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart? Onco Targets Ther. 2014;7:1783–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58:487–93.

    Article  CAS  PubMed  Google Scholar 

  48. Jensen SA, Sørensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significanceto development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol. 2012;69:57–64.

    Article  CAS  PubMed  Google Scholar 

  49. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer. 2005;41:1542–6.

    Article  CAS  PubMed  Google Scholar 

  50. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol. 2006;25:305–9.

    Article  CAS  PubMed  Google Scholar 

  51. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new – an evolving avenue. Circulation. 2016;133(13):1272–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5:2445–52.

    Article  CAS  PubMed  Google Scholar 

  53. Ito H, Okafuji T, Suzuki T. Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessel. 1995;10:178–84.

    Article  CAS  Google Scholar 

  54. Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P, et al. Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res. 2011;14(3):293–308.

    Article  CAS  PubMed  Google Scholar 

  55. Nuver J, Smit AJ, Sleijfer DT, Van Gessel AI, Van Roon AM, Van Der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–6.

    Article  CAS  PubMed  Google Scholar 

  56. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer. 2008;112:1949–53.

    Article  PubMed  Google Scholar 

  57. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.

    Article  CAS  PubMed  Google Scholar 

  58. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002;1:1191–200.

    CAS  PubMed  Google Scholar 

  59. Wood SC, Tang X, Tesfamariam B. Paclitaxel potentiates inflammatory cytokine induced prothrombotic molecules in endothelial cells. J Cardiovasc Pharmacol. 2010;55:276–85.

    Article  CAS  PubMed  Google Scholar 

  60. Mikaelian I, Buness A, de Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, et al. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicol Sci. 2010;117:144–51.

    Article  CAS  PubMed  Google Scholar 

  61. Kachel DL, Martin WJ. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268:42–6.

    CAS  PubMed  Google Scholar 

  62. Samuels BL, Vogelzang NJ, Kennedy BJ. Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy. Cancer Chemother Pharmacol. 1987;19:253–6.

    Article  CAS  PubMed  Google Scholar 

  63. Hansen ES. International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC Working Paper 7/1/2. Shared risk factors for cancer and atherosclerosis – a review of the epidemiological evidence. Mutat Res. 1990;239:163–79.

    Article  CAS  PubMed  Google Scholar 

  64. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649–57.

    Article  PubMed  Google Scholar 

  65. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725–32.

    Article  CAS  PubMed  Google Scholar 

  66. Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54:512–5. https://doi.org/10.1016/j.jjcc.2009.03.009.

    Article  PubMed  Google Scholar 

  67. Gemici G, Cinçin A, Değertekin M, Oktay A. Paclitaxel-induced ST-segment elevations. Clin Cardiol. 2009;32:E94–6. https://doi.org/10.1002/clc.20291.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Shah K, Gupta S, Ghosh J, Bajpai J, Maheshwari A. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther. 2012;8:442–4.

    Article  PubMed  Google Scholar 

  69. Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23:1672–9.

    Article  CAS  PubMed  Google Scholar 

  70. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280–5.

    Article  CAS  PubMed  Google Scholar 

  71. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85.

    Article  CAS  PubMed  Google Scholar 

  72. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. De Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases. Bull Cancer. 1990;77:429–38. [Article in French]

    PubMed  Google Scholar 

  74. Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661–4.

    Article  PubMed  Google Scholar 

  75. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47. https://doi.org/10.1186/2050-6511-15-47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704–12.

    Article  CAS  PubMed  Google Scholar 

  77. Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10:498–501.

    PubMed  Google Scholar 

  78. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and redisposing factors. Cancer Treat Rev. 2013;39:974–84. https://doi.org/10.1016/j.ctrv.2013.03.005.

    Article  CAS  PubMed  Google Scholar 

  79. Dixon A, Nakamura JM, Oishi N, Wachi DH, Fukuyama O. Angina pectoris and therapy with cisplatin, vincristine, and bleomycin. Ann Intern Med. 1989;111:342–3.

    Article  CAS  PubMed  Google Scholar 

  80. Rodriguez J, Collazos J, Gallardo M, Hernando G. Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer. Ann Pharmacother. 1995;29:138–9.

    Article  CAS  PubMed  Google Scholar 

  81. Fukuda M, Oka M, Itoh N, Sakamoto T, Mori H, Hayakawa A, Kohno S. Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer. Intern Med. 1999;38:436–8.

    Article  CAS  PubMed  Google Scholar 

  82. Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9:552–6.

    Article  CAS  PubMed  Google Scholar 

  83. Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12:748–50.

    CAS  PubMed  Google Scholar 

  84. Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15:9–15. https://doi.org/10.1080/10623320802092161.

    Article  CAS  PubMed  Google Scholar 

  85. Lu JI, Carhart RL, Graziano SL, Gajra A. Acute coronary syndrome secondary to fluorouracil infusion. J Clin Oncol. 2006;24:2959–60. https://doi.org/10.1200/JCO.2005.04.0766.

    Article  PubMed  Google Scholar 

  86. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol. 2006;22:251–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13:797–801.

    Article  CAS  PubMed  Google Scholar 

  88. Ozturk B, Tacoy G, Coskun U, Yaman E, Sahin G, Buyukberber S, et al. Gemcitabine-induced acute coronary syndrome: a case report. Med Princ Pract. 2009;18:76–80. https://doi.org/10.1159/000163051.

    Article  PubMed  Google Scholar 

  89. Armitage JD, Montero C, Benner A, Armitage JO, Bociek G. Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma. 2008;8:253–5. https://doi.org/10.3816/CLM.2008.n.035.

    Article  PubMed  Google Scholar 

  90. Ito D, Shiraishi J, Nakamura T, Maruyama N, Iwamura Y, Hashimoto S, et al. Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy. Heart Vessel. 2012;27:634–8. https://doi.org/10.1007/s00380-011-0222-5.

    Article  Google Scholar 

  91. Berliner S, Rahima M, Sidi Y, Teplitsky Y, Zohar Y, Nussbaum B, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Investig. 1990;8(6):583–6.

    Article  CAS  Google Scholar 

  92. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anti-Cancer Drugs. 2008;19:927–9. https://doi.org/10.1097/CAD.0b013e3283100e9c.

    Article  CAS  PubMed  Google Scholar 

  93. Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26:E18–20.

    PubMed  Google Scholar 

  94. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51.

    Article  CAS  PubMed  Google Scholar 

  95. Panella M, Ross JE, Garvin K, Martin A. Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. J Forensic Sci. 2010;55:1384–8. https://doi.org/10.1111/j.1556-4029.2010.01437.x.

    Article  PubMed  Google Scholar 

  96. Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503–9.

    Article  CAS  PubMed  Google Scholar 

  97. Dieckmann KP, Gerl A, Witt J, Hartmann JT. German Testicular Cancer Study Group. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21:1607–11. https://doi.org/10.1093/annonc/mdp597.

    Article  PubMed  Google Scholar 

  98. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, Sleijfer DT. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355:1075–6.

    Article  CAS  PubMed  Google Scholar 

  99. Smith SA, Auseon AJ. Chemotherapy-induced takotsubo cardiomyopathy. Heart Fail Clin. 2013;9:233–42., x. https://doi.org/10.1016/j.hfc.2012.12.009.

    Article  PubMed  Google Scholar 

  100. Dechant C, Baur M, Böck R, Czejka M, Podczeck-Schweighofer A, Dittrich C, et al. Acute reversible heart failure caused by coronary vasoconstriction due to continuous 5-fluorouracil combination chemotherapy. Case Rep Oncol. 2012;5:296–301. https://doi.org/10.1159/000339573.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Qasem A, Bin Abdulhak AA, Aly A, Moormeier J. Capecitabine-induced Takotsubo cardiomyopathy: a case report and literature review. Am J Ther. 2016;23(5):e1188–92.

    Article  PubMed  Google Scholar 

  102. Gianni M, Dentali F, Lonn E. 5 fluorouracil-induced apical ballooning syndrome: a case report. Blood Coagul Fibrinolysis. 2009;20:306–8. https://doi.org/10.1097/MBC.0b013e328329e431.

    Article  CAS  PubMed  Google Scholar 

  103. Numico G, Sicuro M, Silvestris N, Mozzicafreddo A, Trogu A, Malossi A, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol. 2012;30:e218–20. https://doi.org/10.1200/JCO.2012.42.4911.

    Article  PubMed  Google Scholar 

  104. Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F, et al. Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat. 2014;37:487–90. https://doi.org/10.1159/000365536.

    Article  PubMed  Google Scholar 

  105. Ovadia D, Esquenazi Y, Bucay M, Bachier CR. Association between takotsubo cardiomyopathy and axitinib: case report and review of the literature. J Clin Oncol. 2015;33:e1–3. https://doi.org/10.1200/JCO.2013.48.7280.

    Article  PubMed  Google Scholar 

  106. Franco TH, Khan A, Joshi V, Thomas B. Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag. 2008;4:1367–70.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep. 2015;2015 https://doi.org/10.1136/bcr-2014-208203.

    Google Scholar 

  108. Khanji M, Nolan S, Gwynne S, Pudney D, Ionescu A. Tako-Tsubo syndrome after trastuzumab – an unusual complication of chemotherapy for breast cancer. Clin Oncol (R Coll Radiol). 2013;25:329. https://doi.org/10.1016/j.clon.2012.12.007.

    Article  CAS  Google Scholar 

  109. Bhakta S, Flick SM, Cooney MM, Greskovich JF, Gilkeson RC, Remick SC, et al. Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature. Clin Cardiol. 2009;32:E80–4. https://doi.org/10.1002/clc.20685.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Vejpongsa P, Banchs J, Reyes M, Iliescu G, Akinyemi M, Yusuf S, et al. Takotsubo cardiomyopathy in cancer patients: triggers, recovery, and resumption of therapy. J Am Coll Cardiol. 2015;65:A927.

    Article  Google Scholar 

  111. Kobayashi N, Hata N, Yokoyama S, Shinada T, Shirakabe A, Mizuno K. A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nippon Med Sch. 2009;76:27–33.

    Article  PubMed  Google Scholar 

  112. Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40:303–7. https://doi.org/10.1111/j.1445-5994.2009.02144.x.

    Article  CAS  PubMed  Google Scholar 

  113. Grunwald MR, Howie L, Diaz LA Jr. Takotsubo cardiomyopathy and fluorouracil: case report and review of the literature. J Clin Oncol. 2012;30:e11–4. https://doi.org/10.1200/JCO.2011.38.5278.

    Article  PubMed  Google Scholar 

  114. Staff S, Lagerstedt E, Seppänen J, Mäenpää J. Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer. Acta Obstet Gynecol Scand. 2011;90:1296–7. https://doi.org/10.1111/j.1600-0412.2011.01259.x.

    Article  PubMed  Google Scholar 

  115. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95:288–92.

    Article  CAS  PubMed  Google Scholar 

  116. Kuhar CG, Mesti T, Zakotnik B. Digital ischemic events related to gemcitabine: report of two cases and a systematic review. Radiol Oncol. 2010;44:257–61. https://doi.org/10.2478/v10019-010-0020-1.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Zeidman A, Dicker D, Mittelman M. Interferon-induced vasospasm in chronic myeloid leukaemia. Acta Haematol. 1998;100:94–6.

    Article  CAS  PubMed  Google Scholar 

  118. McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud’s phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol. 2013;31:e51–2. https://doi.org/10.1200/JCO.2012.43.2872.

    Article  PubMed  Google Scholar 

  119. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol. 2002;107:133–44. doi: 57631.

    Article  CAS  PubMed  Google Scholar 

  120. Madabhavi I, Revannasiddaiah S, Rastogi M, Gupta MK. Paraneoplastic Raynaud’s phenomenon manifesting before the diagnosis of lung cancer. BMJ Case Rep. 2012;2012 https://doi.org/10.1136/bcr.03.2012.5985.

    Google Scholar 

  121. Stefan O, Vera N, Otto B, Heinz L, Wolfgang G. Stroke in cancer patients: a risk factor analysis. J Neuro-Oncol. 2009;94:221–6. https://doi.org/10.1007/s11060-009-9818-3.

    Article  Google Scholar 

  122. Sanon S, Lenihan DJ, Mouhayar E. Peripheral arterial ischemic events in cancer patients. Vasc Med. 2011;16:119–30. https://doi.org/10.1177/1358863X10388346.

    Article  PubMed  Google Scholar 

  123. Ahn D, Brickner ME, Dowell J. Embolic stroke secondary to an indwelling catheter in a patient with a patent foramen ovale: a case report and review of the literature. Clin Adv Hematol Oncol. 2012;10:335–7.

    PubMed  Google Scholar 

  124. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke. 1994;25:1215–8.

    Article  CAS  PubMed  Google Scholar 

  125. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol. 2010;30:311–9. https://doi.org/10.1055/s-0030-1255224.

    Article  PubMed  Google Scholar 

  126. El Amrani M, Heinzlef O, Debroucker T, Roullet E, Bousser MG, Amarenco P. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology. 1998;51:899–901.

    Article  PubMed  Google Scholar 

  127. Serrano-Castro PJ, Guardado-Santervás P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study. Eur Neurol. 2000;44:63–4. https://doi.org/10.1159/000008197.

    Article  CAS  PubMed  Google Scholar 

  128. Meattini I, Scotti V, Pescini F, Livi L, Sulprizio S, Palumbo V, et al. Ischemic stroke during cisplatin-based chemotherapy for testicular germ cell tumor: case report and review of the literature. J Chemother. 2010;22:134–6. https://doi.org/10.1179/joc.2010.22.2.134.

    Article  CAS  PubMed  Google Scholar 

  129. Periard D, Boulanger CM, Eyer S, Amabile N, Pugin P, Gerschheimer C, et al. Are circulating endothelial-derived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke. 2007;38:1636–8. https://doi.org/10.1161/STROKEAHA.106.479733.

    Article  CAS  PubMed  Google Scholar 

  130. Martín GG, Fernández SP, Castro VS, Cueto OH, Acebal MR. Vertebral artery occlusion after chemotherapy. Stroke. 2008;39:e38.; author reply e39. https://doi.org/10.1161/STROKEAHA.107.503987.

    Article  PubMed  Google Scholar 

Download references

Disclosures

CGT received speaking fees from Alere.

Funding

CGT is funded by a Federico II University/Ricerca di Ateneo grant.

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Valentina Mercurio

  2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Giulio Agnetti

  3. DIBINEM, University of Bologna, Bologna, Italy

    Giulio Agnetti

  4. Clinical and Biological Sciences, AOU San Luigi Gonzaga, Orbassano, Italy

    Pasquale Pagliaro

  5. Department of Translational Medical Sciences, Federico II University, Naples, Italy

    Carlo G. Tocchetti

Authors
  1. Valentina Mercurio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulio Agnetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pasquale Pagliaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlo G. Tocchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo G. Tocchetti .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy

    Antonio Russo

  2. University of Palermo, School of Medicine, Palermo, Italy

    Giuseppina Novo

  3. Department of Cardiology, University of Liège, Liege, Belgium

    Patrizio Lancellotti

  4. Temple University College of Science and Technology, Philadelphia, PA, USA

    Antonio Giordano

  5. Cardiology Department, University of Lisbon, Lisbon, Portugal

    Fausto J. Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mercurio, V., Agnetti, G., Pagliaro, P., Tocchetti, C.G. (2019). Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy. In: Russo, A., Novo, G., Lancellotti, P., Giordano, A., Pinto, F. (eds) Cardiovascular Complications in Cancer Therapy. Current Clinical Pathology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-93402-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93402-0_2

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-93401-3

  • Online ISBN: 978-3-319-93402-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation